New Alzheimer’s Trial Reveals Surprising Insight on Brain Health
Novo Nordisk, the pharmaceutical company behind popular GLP-1 medications like Wegovy and Ozempic, recently announced that its phase 3, two-year trial examining GLP-1 medications for Alzheimer's failed to produce a significant reduction in disease progression.
While these results are discouraging, they may have revealed something vital about Alzheimer’s treatment.
In this video, Dr. Bret Scher breaks down the recent failure of Novo Nordisk’s evoke and evoke+ trials and what it teaches us about the limitations of a drug-only approach to Alzheimer’s treatment.
Key topics covered:
Why GLP-1s may…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.